Status:

COMPLETED

Vancomycin for the Treatment of NAAT(+)/Toxin(-) C. Difficile

Lead Sponsor:

Medical College of Wisconsin

Conditions:

Clostridium Difficile Infection

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This study proposes to: 1. Characterize the impact of oral vancomycin on C. difficile loads after end of treatment compared to a placebo group. 2. Determine the effect of oral vancomycin on structura...

Detailed Description

Clostridium difficile infection (CDI) is considered the most frequent healthcare associated infection in the US, causing almost half a million cases per year with an estimated annual cost of 4.8 billi...

Eligibility Criteria

Inclusion

  • Must be at least 18 years of age at time of consent.
  • Presence of loose stools triggering clinical C. difficile NAAT/toxin EIA testing.
  • Having both C. difficile NAAT (+) and C. difficile toxin EIA (-).
  • Admitted outside the hematology-oncology unit.
  • Must be willing to keep a study supplied drug diary

Exclusion

  • Presence of sepsis. Sepsis will be defined as a Sequential \[Sepsis-related\] Organ Failure Assessment (SOFA) score of 2 points or more as per 2016 definitions.
  • Inability to take oral medications.
  • Unwillingness or inability to provide written informed consent.
  • Has a documented allergy to vancomycin.
  • Has a documented life expectancy shorter than treatment course (14 days).
  • Unwilling or unable to collect stool samples in the outpatient setting after discharge.
  • Diagnosis of C. difficile colitis \[NAAT(+) and toxin EIA(+)\] in the preceding 3 months from enrollment.
  • Received oral vancomycin during their current hospitalization, excluding empiric treatment given while pending C. difficile NAAT/toxin EIA results. Intravenous vancomycin is not an exclusion criterion.
  • Women known to be pregnant or lactating during the study.

Key Trial Info

Start Date :

July 17 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2021

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT03827447

Start Date

July 17 2019

End Date

June 30 2021

Last Update

October 20 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical College of Wisconsin, Inc.

Milwaukee, Wisconsin, United States, 53226